Connect with us

Government

“It’s The Roaring ’20s Again”: Goldman Boosts Forecast, Now Sees S&P Hitting 4,600 In 2022

"It’s The Roaring ’20s Again": Goldman Boosts Forecast, Now Sees S&P Hitting 4,600 In 2022

Published

on

"It's The Roaring '20s Again": Goldman Boosts Forecast, Now Sees S&P Hitting 4,600 In 2022 Tyler Durden Wed, 11/11/2020 - 08:57

Two days ago, JPMorgan - which just two weeks ago predicted that "an orderly Trump victory was the most favorable outcome for equities (upside to ~3,900)" - engaged in some pretty blatant revisionism and not only flip-flopped on its view of how Congressional gridlock would impact markets, which it now sees as the optimal outcome for stocks, but in a note saying that the "Vaccine Rotation, Subsiding Risks" are nothing short of "Market Nirvana", boosted its September market price targets, and now sees the S&P reaching 3,600 before year-end, 4,000 by early next year, and "a good potential for the market to move even higher (~4,500) by the end of next year."

Well, since there is never just one revisionist Wall Street strategist, this morning Goldman Sachs copied JPM's revised forecast almost verbatim, and in a note from David Kostin which sees 2021 as a redux of the "roaring '20s" - which as everyone knows ended with the Great Depression and eventually World War II...

...  the bank raised its 2020 S&P 500 target to 3700 from 3600; it also forecasts the S&P 500 will climb by 16% to 4300 at year-end 2021 and gain 7% to reach 4600 by the end of 2022.

The reason? As Kostin, who curiously had already factored in positive vaccine news into his forecasts explains, "a vaccine is a more important development for the economy and markets than the prospective policies of a Biden presidency." In other words, Goldman's top strategist is double counting positive vaccine news to chase and justify the market's surge. But hoping that nobody remembers his previous positive take on vaccine news, he says that the results from Pfizer "that its COVID-19 vaccine has an efficacy rate greater than 90% is a positive event that will allow society to gradually normalize during 2021."

It's not just Covid: as Kostin likes to say, "elections have consequences, both for policies and markets." And while Goldman sees Biden as the 46th President of the United States, "the upcoming 117th Congress (2021-2023) will likely remain divided but will depend on the results of two run-off Senate elections in Georgia on January 5th. Politics is policy and uncertainty will remain elevated until then. A divided government means little scope for major legislative changes, although trade and regulatory policy stances will likely differ relative to the Trump administration. Unified control would mean more fiscal spending but also higher individual and corporate tax rates."

Nothing new here; where there is supposedly something new is in Kostin's latest take on how quickly the vaccine would impact society, and how alleged eradication of the virus will affect the company's latest 2021 outlook, to wit:

The virus and the vaccine

Despite investor focus on the prospective policy implications of the Biden presidency, the vaccine for COVID-19 is a more important determinant of the path of both the economy and stock market in 2021. The positive preliminary phase 3 trial results from PFE revealed that its COVID-19 vaccine exhibited an efficacy rate greater than 90%, well above what many medical experts had anticipated. However, the timing was consistent with the expectation by Goldman Sachs Biotechnology and Pharmaceutical equity analysts that a vaccine would be identified before year-end. We expect the PFE vaccine, and perhaps other vaccine candidates, will receive emergency use authorization (EUA) by January, and sufficient doses will be available to vaccinate the US population during the first-half of 2021.

In a world where covid is defeated, this clearly would ripple through to corporate earnings, especially at banks where loan loss provisions would tumble. This is what Goldman thinks happens to earnings next:

We lift our S&P 500 EPS growth estimates to $136 in 2020 (-17%), $175 in 2021 (+29%), $195 in 2022 (+12%), $207 in 2023 (+6%), and $218 in 2024 (+5%). Our revised growth estimates are roughly in line with our previous estimates, but the level of 2024 EPS is $4 or 2% higher to reflect the increased starting point of 2020 profits. Our increased estimates primarily reflect much better-than-expected results in 3Q. S&P 500 EPS in 3Q 2020 was expected to fall by 21% but realized growth of just -8% (+$5 swing).

Bottom-up analyst revision sentiment is now extremely positive and we expect consensus estimates will have additional upward revisions. Our 2021 top-down EPS forecast is 4% above the consensus bottom-up estimate of $168 and 13% above the median consensus top-down estimate of $155.

Goldman is also fully bulled up on the broader economic environment next year, seeing a "continued V-shaped recovery":

Goldman Sachs Economics US GDP growth forecasts reflect a continued “V-shaped” recovery and are well above-consensus at +5.3% in 2021 (consensus +3.8%) and +3.8% in 2022 (consensus +2.8%), followed by growth of +2.4% in 2023. In part due to this optimistic forecast for an economic rebound from the pandemic-induced recession, our 2021 earnings forecast is also above consensus.

Outside of economic activity, a weakening USD and slack in the labor market should support S&P 500 sales and margins, respectively. The US unemployment rate registered 6.9% in October, well above the estimated natural rate of unemployment (4.4%). Our top-down model demonstrates that a loose labor market is typically positive for earnings growth, as wage growth exerts limited pressure on margin growth. Our FX strategists expect the trade-weighted US Dollar is in a structural downtrend, which typically acts as a tailwind to S&P 500 revenues, particularly for international-facing sectors. Their FX estimates assume the USD weakens by 5% vs. the Yen (to 100) and by 6% vs. the Euro (to 1.25).

To be sure, Goldman had some problems justifying a 1000 point surge in 2 years when looking at already record-stretched valuations, which the bank admits are currently in the 92% percentile...

... adding that the bank's 2022 price target is based on a - drumroll - 22.1x PE multiple!!!

The S&P 500 index levels we forecast imply a modest P/E multiple expansion next year. The market currently trades at 20.3x our top-down 2021 EPS estimate. Our DDM-derived price target implies that during 2021 the forward P/E multiple will expand by 2x to 22.1x. The implied absolute valuation at year-end 2021 would rank at the 94th percentile vs. history.

However, our year-end 2021 forecast for valuations relative to bond yields would rank in just the 51st percentile vs. history. Accommodative Fed policy and low interest rates make equities appear attractive on a relative basis vs. fixed income alternatives, pushing investors out on the risk curve. With the earnings yield gap of 323 bp above the projected year-end 2021 Treasury, our price target implies a relative valuation roughly in line with the long-term average, less extreme than signals from absolute valuation metrics (see Exhibit 12).

... but here too the company found a "deus-ex" loophole:  record low interest rates which will allow the equity risk premium to compress further:

The backdrop of low interest rates and subdued policy uncertainty that we anticipate during the next two years will be constructive for equity valuations. Our valuation framework relies on the cost of equity, which in turn depends on interest rates and the equity risk premium. The key drivers of our ERP model include breakeven inflation, policy uncertainty, consumer confidence, and change in the size of the Fed’s balance sheet.

Interest rates: We assume stable Fed policy and limited yield curve steepening. Given the Fed’s new average inflation targeting (AIT) framework and its forward guidance for the funds rate, Goldman Sachs Economics forecasts the first hike in the funds rate will not occur until 2025. We assume higher breakeven inflation will drive modest yield curve steepening as the ten-year US Treasury yield climbs from 95 bp today to 1.3% at year-end 2021 and 1.7% by the end of 2022. Diminished prospects of massive fiscal spending that might have occurred under a Democratic sweep coupled with extremely low bond yields globally will limit the rise in nominal US yields.

Equity risk premium: Improving growth expectations and falling uncertainty will compress the ERP. Our economists’ baseline forecast for fiscal stimulus and vaccine approval should drive an improvement in growth expectations, breakeven inflation, and consumer confidence, in turn pushing the ERP lower. The economic policy uncertainty index has averaged 227 during the last year, 100% above the long-term average, and has kept the ERP elevated (Exhibit 9). However, we expect a divided government will reduce uncertainty sharply by year-end 2022 (to 125, in line with the long-term average).

So basically the entire thesis falls apart if yields jump as markets start pricing in rate hikes and runaway inflation. But we digress...

Which brings us to Goldman's baseline assumptions for 2021 which all have to be justified for the S&P to hit 4,600 by the end of 2022:

  1. At least one vaccine is approved by the FDA and administered to a large portion of the US population.
  2. The federal government is divided with the Republicans maintaining majority control of the Senate following the Georgia elections.
  3. Policy uncertainty declines.
  4. The economy continues its “V-shaped” recovery.
  5. S&P 500 profits rebound sharply from their pandemic lows.
  6. The Fed remains on hold with a stable fed funds rate of 0-25 bp.
  7. The yield curve steepens but ten-year Treasury yields climb only modestly.

Under these conditions - and really Goldman will immediately flip its view as soon as the S&P tumbles because both JPM and Goldman have demonstrated that it is always and only price that sets the market narrative - Goldman forecast S&P 500 will rise by an additional 11% to reach 4100 by mid-year and end 2021 at 4300 (+5%; for a full-year return of 16% next year) and climb by 7% to reach 4600 by year-end 2022.

To justify this berserk forecast which can only happen in a world where there is no business cycle and where (digital) money literally grows on magic money trees, Goldman writes that "the S&P 500 annual return has been between 10% and 20% roughly 25% of the time since 1982."

Because, supposedly the logic goes, the current helicopter money, $28 trillion in debt environment is somehow comparable to everything that happened in previous years.

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Government

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Trending